# RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

> **NCT05996952** · PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 77 (estimated)

## Conditions studied

- Non-muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** RC48-ADC

## Key facts

- **NCT ID:** NCT05996952
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08
- **Primary completion:** 2025-08
- **Final completion:** 2026-08
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2023-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05996952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05996952, "RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05996952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*